Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

التفاصيل البيبلوغرافية
العنوان: Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
المؤلفون: Alexandre Vinaud Hirayama, Salvatore Fiorenza, Jordan Gauthier, Jenna M. Voutsinas, Qian Vicky Wu, Erik L. Kimble, Barbara S. Pender, Delaney R. Kirchmeier, Henna A. Di, Ryan D. Cassaday, Aude G. Chapuis, Damian J. Green, Hans-Peter Kiem, Filippo Milano, Mazyar Shadman, Brian G. Till, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
المصدر: Blood. 140:7447-7449
بيانات النشر: American Society of Hematology, 2022.
سنة النشر: 2022
مصطلحات موضوعية: Immunology, Cell Biology, Hematology, Biochemistry
تدمد: 1528-0020
0006-4971
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::f6ccf9df348782fb94a86d508def73fb
https://doi.org/10.1182/blood-2022-168185
رقم الأكسشن: edsair.doi...........f6ccf9df348782fb94a86d508def73fb
قاعدة البيانات: OpenAIRE